Scil Proteins GmbH is a privately financed bio-technology company formed in 1999 by Stefan Engelhorn, Ulrike Fiedler und Rainer Rudolph; today it is part of the BioNet Group Munich). In 2005 the company, with an initial six employees, became Scil Proteins Production GmbH, which today produces effective pharmaceutical ingredients according to GMP (Good Manufacturing Practice), one of the highest quality standards existing today. Today both companies have a total of over 85 highly-specialized employees qualified in biology, biochemistry and pharmaceuticals.
Scil Proteins is active in two business areas. One is the development of new and innovative effective pharmaceutical ingredients such as Affilin® or MIA2 Zytokin used to combat liver fibrosis. While most programmes are in the preliminary R&D area, the Affilin® technology has been made available to international partners in the pharmaceuticals industry since 2008.
The other area is the contract manufacture of recombinant proteins for pre-clinical and clinical studies and for supplying market demand. Besides manufacturing, it also offers cell lines, process, analytical and protein-folding development.
Year of foundation1999
(Scil Proteins & Scil Proteins Production)
Business activityAffilin®, MIA2, contract manufacturing, process development, recombinant
proteins, protein folding